|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||356.470 g·mol−1|
|3D model (JSmol)|
AB-CHMINACA is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor (Ki = 0.78 nM) and CB2 receptor (Ki = 0.45 nM) and fully substitutes for Δ9-THC in rat discrimination studies, while being 16x more potent. Continuing the trend seen in other cannabinoids of this generation, such as AB-FUBINACA and AB-PINACA, it contains a valine amino acid amide residue as part of its structure, where older cannabinoids contained a naphthyl or adamantane residue.
There have been a number of reported cases of seizures, deaths, and psychotic episodes in relation to this synthetic cannabinoid.
In 2015, AB-CHMINACA became a Schedule I controlled substance in the United States.
AB-CHMINACA is an Anlage II controlled substance in Germany as of May 2015.
As of October 2015 AB-CHMINACA is a controlled substance in China.
AB-CHMINACA is illegal in Switzerland as of December 2015.
AB-CHMINACA is an illegal substance in Russian Federation.